|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.
|
30061737 |
2018 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
CTD_human |
Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.
|
30061737 |
2018 |
|
Paroxysmal atrial fibrillation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.
|
30061737 |
2018 |
|
Persistent atrial fibrillation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.
|
30061737 |
2018 |
|
familial atrial fibrillation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.
|
30061737 |
2018 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
RGD |
Fatty acid transporter levels and palmitate oxidation rate correlate with ejection fraction in the infarcted rat heart.
|
17034771 |
2006 |
|
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Joint Association Analysis Identified 18 New Loci for Bone Mineral Density.
|
30690781 |
2019 |
|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
By contrast, relatively low SLC27A6 expression in tumorigenic breast cancer cell Hs578T when compared to H184B5F5/M10.
|
30911270 |
2019 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our study, unraveled FATP1 as a putative therapeutic target in breast cancer (BC).
|
31575907 |
2019 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our study, unraveled FATP1 as a putative therapeutic target in breast cancer (BC).
|
31575907 |
2019 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
By contrast, relatively low SLC27A6 expression in tumorigenic breast cancer cell Hs578T when compared to H184B5F5/M10.
|
30911270 |
2019 |
|
Gestational Diabetes
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
High pre-pregnancy BMI and GDM were associated with decreased placental FATP1, FATP4, EL and increased FAT/CD36 and FATP6 expressions.
|
28864004 |
2017 |
|
Obesity
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Pre-existing maternal obesity and GDM are associated with decreased expression in genes involved in fatty acid uptake and intracellular transport (LPL, FATP2, FATP6, FABPpm and ASCL1), triacylglyceride (TAG) biosynthesis (MGAT1,7 MGAT2 and DGAT1), lipogenesis (FASN) and lipolysis (PNPLA2, HSL and MGLL).
|
24262292 |
2014 |
|
Gestational Diabetes
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Pre-existing maternal obesity and GDM are associated with decreased expression in genes involved in fatty acid uptake and intracellular transport (LPL, FATP2, FATP6, FABPpm and ASCL1), triacylglyceride (TAG) biosynthesis (MGAT1,7 MGAT2 and DGAT1), lipogenesis (FASN) and lipolysis (PNPLA2, HSL and MGLL).
|
24262292 |
2014 |
|
Metabolic Syndrome X
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A total of 755 male participants from a Metabolic Intervention Cohort Kiel were genotyped for the FATP6-7T>A polymorphism (rs2526246) and phenotyped for features of the metabolic syndrome.
|
21920065 |
2012 |
|
Metabolic Syndrome X
|
0.020 |
Biomarker
|
disease |
BEFREE |
By logistic regression using a dominant model (homozygous for the common allele versus carriers of the rare allele), the odds ratio [95% confidence interval] for the MS were: 0.91 [0.68-1.22] for FATP1, 0.93 [0.68-1.28] for TNF-alpha, 0.97 [0.73-1.29] for UCP3, 1.06 [0.80-1.40] for LEP, and 1.12 [0.84-1.48] for GNB3 SNPs.
|
15978856 |
2006 |
|
Obesity
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Insulin did not affect FATP-1 mRNA expression in skeletal muscle in obese nondiabetic or in type 2 diabetic subjects nor in subcutaneous adipose tissue in any of the three groups.
|
11052962 |
2000 |
|
Experimental Organism Basal Cell Carcinoma
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In vitro, we verified that FA and estradiol stimulated FATP1/SLC27A1 expression in BCCs.
|
31575907 |
2019 |
|
Carcinoma, Basal Cell
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In vitro, we verified that FA and estradiol stimulated FATP1/SLC27A1 expression in BCCs.
|
31575907 |
2019 |
|
Fetal Growth Retardation
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
MVM expression of FATP6 and CD36 was significantly increased in IUGR.
|
29463583 |
2018 |
|
Atherosclerotic lesion
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lack of myeloid Fatp1 increases atherosclerotic lesion size in Ldlr<sup>-/-</sup> mice.
|
29035781 |
2017 |
|
Fibroid Tumor
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we examined the expression of glucose transporters (GLUT-1, GLUT-4) and fatty acids transporters (FAT/CD36, FATP-1, FATP-4) at transcript and protein levels as well as cytosolic fatty acid binding proteins (H-FABP, ACBP) in human fibroids (n=74, size up to 3cm diameter) and compared with pair-matched healthy myometrium.
|
26932421 |
2016 |